Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves’ Orbitopathy
Table 2
Risk factors associated with liver dysfunction during and/or after intravenous methylprednisolone pulse therapy for Graves’ orbitopathy.
Number of patients
Liver dysfunction
Univariate
Multivariate analysis
ALT (IU/L)
Fisher’s exact probability test
Multinomial logit model for an unordered response
<40
40–100
100–300
>300
95% CI
2 sided
2 × 4
Lower
Upper
value
Total
175
96 (55%)
62 (35%)
10 (6%)
7 (4%)
Male
57
21 (37%)
31 (54%)
5 (9%)
0 (0%)
= 18.34
Female
118
75 (64%)
31 (26%)
5 (4%)
7 (6%)
= 0.000278
0.1348
1.646
0.01895
HBcA b (+)
43
15 (35%)
24 (56%)
2 (5%)
2 (5%)
= 11.01
= 0.01125
HCVAb (+)
17
6 (35%)
6 (35%)
4 (24%)
1 (6%)
= 11.94
= 0.01132
HBcAb (+) and/or HCVAb (+)
53
19 (36%)
26 (49%)
5 (9%)
3 (6%)
= 11.36 = 0.008867
−0.245
1.417
0.1846
HBcAb (−) HCVAb (−)
122
77 (63%)
36 (30%)
5 (4%)
4 (3%)
—
Age
>50 yr
95
41 (43%)
45 (47%)
8 (8%)
1 (1%)
= 20.72
0.03396
1.553
0.03972
50 yr
80
55 (69%)
17 (21%)
2 (3%)
6 (8%)
= 0.00004
IVMP
>8 g
118
57 (48%)
47 (40%)
9 (8%)
5 (4%)
= 7.187
0.1012
1.640
0.02426
8 g
57
39 (89%)
15 (26%)
1 (2%)
2 (4%)
= 0.06052
Smoking
(+)
57
26 (46%)
24 (42%)
4 (7%)
3 (5%)
= 2.969
(−)
118
70 (59%)
38 (32%)
6 (5%)
4 (3%)
= 0.3887
Alcohol
(+)
48
24 (50%)
19 (40%)
3 (6%)
2 (4%)
= 0.6445
(−)
127
72 (57%)
43 (34%)
7 (6%)
5 (4%)
= 0.9176
Compared to patients without HBcAb or HCVAb. ALT, alanine aminotransferase; HBcAb, anti-hepatitis B core antibody; HCVAb, anti-hepatitis C virus antibody; IVMP, intravenous injection of methylprednisolone.
